TY - JOUR
T1 - Early-infantile onset epilepsy and developmental delay caused by bi-allelic GAD1 variants
AU - SYNAPS Study Group
AU - Neuray, Caroline
AU - Maroofian, Reza
AU - Scala, Marcello
AU - Sultan, Tipu
AU - Pai, Gurpur S.
AU - Mojarrad, Majid
AU - Khashab, Heba El
AU - deHoll, Leigh
AU - Yue, Wyatt
AU - Alsaif, Hessa S.
AU - Zanetti, Maria N.
AU - Bello, Oscar
AU - Person, Richard
AU - Eslahi, Atieh
AU - Khazaei, Zaynab
AU - Feizabadi, Masoumeh H.
AU - Efthymiou, Stephanie
AU - El-Bassyouni, Hala T.
AU - Soliman, Doaa R.
AU - Tekes, Selahattin
AU - Ozer, Leyla
AU - Baltaci, Volkan
AU - Khan, Suliman
AU - Beetz, Christian
AU - Amr, Khalda S.
AU - Salpietro, Vincenzo
AU - Jamshidi, Yalda
AU - Alkuraya, Fowzan S.
AU - Houlden, Henry
AU - Groppa, Stanislav
AU - Karashova, Blagovesta Marinova
AU - Nachbauer, Wolfgang
AU - Boesch, Sylvia
AU - Arning, Larissa
AU - Timmann, Dagmar
AU - Cormand, Bru
AU - Pérez-Dueñas, Belen
AU - Di Rosa, Gabriella
AU - Goraya, Jatinder S.
AU - Sultan, Tipu
AU - Mine, Jun
AU - Avdjieva, Daniela
AU - Kathom, Hadil
AU - Tincheva, Radka
AU - Banu, Selina
AU - Pineda-Marfa, Mercedes
AU - Veggiotti, Pierangelo
AU - Ferrari, Michel D.
AU - Verrotti, Alberto
AU - Kirmani, Salman
N1 - Funding Information:
We thank all families and collaborators for providing detailed clinical data and samples to conduct this study. This study was supported by grants from The MRC (MR/ S01165X/1, MR/S005021/1, G0601943), The National Institute for Health Research University College London Hospitals Biomedical Research Centre, Rosetree Trust, Ataxia UK, MSA Trust, Brain Research UK, Sparks GOSH Charity, Muscular Dystrophy UK (MDUK), Muscular Dystrophy Association (MDA USA). The families were collected as part of the SYNaPS Study Group collaboration funded by The Wellcome Trust and strategic award (Synaptopathies) funding (WT093205 MA and WT104033AIA). This research was conducted as part of the Queen Square Genomics group at University College London, supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.
Publisher Copyright:
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Gamma-aminobutyric acid (GABA) and glutamate are the most abundant amino acid neurotransmitters in the brain. GABA, an inhibitory neurotransmitter, is synthesized by glutamic acid decarboxylase (GAD). Its predominant isoform GAD67, contributes up to ∼90% of base-level GABA in the CNS, and is encoded by the GAD1 gene. Disruption of GAD1 results in an imbalance of inhibitory and excitatory neurotransmitters, and as Gad1-/- mice die neonatally of severe cleft palate, it has not been possible to determine any potential neurological dysfunction. Furthermore, little is known about the consequence of GAD1 disruption in humans. Here we present six affected individuals from six unrelated families, carrying bi-allelic GAD1 variants, presenting with developmental and epileptic encephalopathy, characterized by early-infantile onset epilepsy and hypotonia with additional variable non-CNS manifestations such as skeletal abnormalities, dysmorphic features and cleft palate. Our findings highlight an important role for GAD1 in seizure induction, neuronal and extraneuronal development, and introduce GAD1 as a new gene associated with developmental and epileptic encephalopathy.
AB - Gamma-aminobutyric acid (GABA) and glutamate are the most abundant amino acid neurotransmitters in the brain. GABA, an inhibitory neurotransmitter, is synthesized by glutamic acid decarboxylase (GAD). Its predominant isoform GAD67, contributes up to ∼90% of base-level GABA in the CNS, and is encoded by the GAD1 gene. Disruption of GAD1 results in an imbalance of inhibitory and excitatory neurotransmitters, and as Gad1-/- mice die neonatally of severe cleft palate, it has not been possible to determine any potential neurological dysfunction. Furthermore, little is known about the consequence of GAD1 disruption in humans. Here we present six affected individuals from six unrelated families, carrying bi-allelic GAD1 variants, presenting with developmental and epileptic encephalopathy, characterized by early-infantile onset epilepsy and hypotonia with additional variable non-CNS manifestations such as skeletal abnormalities, dysmorphic features and cleft palate. Our findings highlight an important role for GAD1 in seizure induction, neuronal and extraneuronal development, and introduce GAD1 as a new gene associated with developmental and epileptic encephalopathy.
KW - Cleft palate
KW - Epilepsy
KW - GAD1
KW - Muscle weakness
KW - Neurodevelopmental delay
UR - http://www.scopus.com/inward/record.url?scp=85090075296&partnerID=8YFLogxK
U2 - 10.1093/brain/awaa178
DO - 10.1093/brain/awaa178
M3 - Article
C2 - 32705143
AN - SCOPUS:85090075296
SN - 0006-8950
VL - 143
SP - 2388
EP - 2397
JO - Brain
JF - Brain
IS - 8
ER -